EUVIMEDEUVIMED entdecken
Crossref

Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells

Feyzanur Caldiran, Caglar Berkel, Esra Yilmaz, Burak Kucuk, Aslihan Hatun Cacan, Senol Citli, Emel Canpolat, Ercan Cacan

Biochemical and Biophysical Research Communications · 2023

DOI: 10.1016/j.bbrc.2023.06.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Feyzanur Caldiran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tokat Gaziosmanpasa University, Faculty of Science and Art, Department of Molecular Biology and Genetics, Tokat, Turkiye. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Colorectal Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Tokat Gaziosmanpaşa University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer is one of the most common cancers worldwide, affecting the colon and rectum. A major problem in the treatment of colorectal cancer is acquired chemoresistance, including resistance against death receptor-induced apoptosis. Therefore, investigating new biomarkers for the treatment of the disease and sensitization strategies against TRAIL might be of high clinical importance. TNFRSF10A/B are known as death receptors for TRAIL-induced apoptotic cell death. In this study, we used multiple bioinformatic tools and experimental analyses to investigate the role of TRAIL receptors TNFRSF10A and TNFRSF10B in colorectal cancer. We also identified the potential effect of bortezomib and epirubicin in the induction of TRAIL-mediated apoptotic cell death. Here, we showed that TNFRSF10 A/B expressions are upregulated in various tumor types, including COAD, and its high expression is decreased with the different clinicopathological parameters in COAD. We also found an association between TNFRSF10 A/B expression and tumor molecular subtypes. We further detected the association between the expression of TNFRSF10 A/B and immune cell tumor infiltration, including B cells, CD8+ T cells, neutrophils and dendritic cells. In addition, we showed that combining bortezomib and epirubicin treatment leads to the upregulation of TNFRSF10 A/B in colorectal cancer cells in vitro. The increase in the expression of death receptors was correlated with higher active caspase-3 levels following the incubation of cells with recombinant TRAIL protein, which is a ligand for TNFRSF10 A/B receptors. Our results suggest that TNFRSF10 A/B may be a marker to differentiate tumor molecular subtypes in colorectal cancer. The expression of TNFRSF10 A/B may be associated with the recruitment of immune cells into tumors and the development of tumor suppression. The combination of bortezomib and epirubicin treatment might sensitize colorectal cancer cells to TRAIL-induced apoptosis via the upregulation of death receptor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesColorectal NeoplasmsHumansApoptosisBortezomibCell Line, TumorEpirubicinReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing Ligand

Stichwörter der Autor:innen

BortezomibColorectal cancerEpirubicinTNFRSF10ATNFRSF10BTRAIL-DR

Substanzen

BortezomibEpirubicinReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing Ligand

Autor:innen und Institutionen

  • Tokat Gaziosmanpasa University, Faculty of Science and Art, Department of Molecular Biology and Genetics, Tokat, Turkiye.
  • Tokat Gaziosmanpasa University, Department of Medical Services and Techniques, Erbaa, Tokat, Turkiye.
  • Recep Tayyip Erdogan University, Faculty of Medicine, Department of Medical Genetics, Rize, Turkiye.
  • Tokat Gaziosmanpasa University, Faculty of Science and Art, Department of Molecular Biology and Genetics, Tokat, Turkiye. Electronic address: ercan.cacan@gop.edu.tr.

Förderung

  • Tokat Gaziosmanpaşa University

Zitieren

APA

Caldiran, F., Berkel, C., Yilmaz, E., Kucuk, B., Cacan, A. H., Citli, S., Canpolat, E., & Cacan, E. (2023). Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.06.015

Vancouver

Caldiran F, Berkel C, Yilmaz E, Kucuk B, Cacan AH, Citli S, et al. Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.06.015

BibTeX
@article{Caldiran2023,
  author = {Caldiran, Feyzanur and Berkel, Caglar and Yilmaz, Esra and Kucuk, Burak and Cacan, Aslihan Hatun and Citli, Senol and Canpolat, Emel and Cacan, Ercan},
  title = {Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2023},
  doi = {10.1016/j.bbrc.2023.06.015}
}
Kostenlos starten →